Post-marketing safety signals of Wilson’s disease therapies: evidence from FAERS and VigiBase.

HOME
>
論文・技術情報
>
Post-marketing safety signals of Wilson’s disease therapies: evidence from FAERS and VigiBase.

アブストラクト
ジャーナル名	Orphanet journal of rare diseases
Pubmed追加日	2026/3/10
投稿者	Tezel-Yalcin, Hulya; Yalcin, Nadir; Allegaert, Karel; Erkekoglu, Pinar
組織名	Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Hacettepe;University, Ankara, Turkiye, 06230, Turkey.;Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University,;Ankara, Turkiye, 06230, Turkey. nadir.yalcin@hacettepe.edu.tr.;Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and;Pharmacological Sciences, KU Leuven, Leuven, 3000, Belgium.;Department of Development and Regeneration, KU Leuven, Leuven, 3000, Belgium.;Department of Hospital Pharmacy, Erasmus MC, Rotterdam, 3015 GD, The Netherlands.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/41803965/